A soluble LAG-3 protein (eftilagimod alpha) and an anti-PD-L1 antibody (avelumab) tested in a phase I trial: a new combination in immuno-oncology

BACKGROUND: Eftilagimod alpha (efti) is a major histocompatibility complex class II agonist activating antigen-presenting cells which leads to greater systemic type 1 T helper response and more cytotoxic CD8+ T-cell activation. This phase I trial evaluated the administration of efti, a soluble lymph...

Descripción completa

Detalles Bibliográficos
Autores principales: Al-Batran, S.-E., Mueller, D.W., Rafiyan, M.-R., Kiselicki, D., Atmaca, A., Habibzada, T., Mueller, C., Brignone, C., Triebel, F., Loose, M., Schaaf, M., Sookthai, D., Eickhoff, R., Jaeger, E., Goetze, T.O.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2023
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10594027/
https://www.ncbi.nlm.nih.gov/pubmed/37742484
http://dx.doi.org/10.1016/j.esmoop.2023.101623

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10594027/
https://www.ncbi.nlm.nih.gov/pubmed/37742484
http://dx.doi.org/10.1016/j.esmoop.2023.101623

Ejemplares similares